Norges Bank Mersana Therapeutics, Inc. Transaction History

Norges Bank

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 07, 2021	SELL	$15.31 - $26.52 $205,337 - $355,686	-13,412 Closed	0 $0
Q4 2020 Mar 02, 2021	BUY	$16.84 - $27.59 $225,858 - $370,037	13,412 New	13,412 $357,000
Q4 2020 Feb 10, 2021	SELL	$16.84 - $27.59 $225,858 - $370,037	-13,412 Closed	0 $0
Q3 2020 Nov 12, 2021	BUY	$16.2 - $25.7 $217,274 - $344,688	13,412 New	13,412 $250,000
Q2 2018 Jul 23, 2018	SELL	$14.2 - $22.68 $284,000 - $453,600	-20,000 Closed	0 $0
Q1 2018 May 15, 2019	BUY	$13.56 - $18.48 $271,200 - $369,600	20,000 New	20,000 $315,000
Q1 2018 May 09, 2018	SELL	$13.56 - $18.48 $271,200 - $369,600	-20,000 Closed	0 $0
Q4 2017 Mar 05, 2018	BUY	$14.95 - $19.9 $299,000 - $398,000	20,000 New	20,000 $329,000
Q4 2017 Feb 09, 2018	SELL	$14.95 - $19.9 $299,000 - $398,000	-20,000 Closed	0 $0
Q3 2017 Nov 13, 2018	BUY	$14.8 - $18.06 $296,000 - $361,200	20,000 New	20,000 $346,000
Q3 2017 Nov 07, 2017	SELL	$14.8 - $18.06 $296,000 - $361,200	-20,000 Closed	0 $0
Q2 2017 Jul 24, 2018	BUY	N/A	20,000	20,000 $279,000

136

101M

77.2K

453K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $44.7M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.